Exploration of the efficacy of anti‐immunoglobulin E monoclonal antibodies in the treatment of allergic asthma

Abstract

The present study aims to evaluate the efficacy of an anti‐immunoglobulin E monoclonal antibody (omalizumab) in the treatment of allergic asthma (AS). A total of 34 patients with moderate‐to‐severe bronchial asthma admitted to the Respiratory Department of Tianjin First Central Hospital between September 2019 and September 2021 were enrolled in this study. The patients were treated with omalizumab in addition to conventional inhaled corticosteroids + long‐acting β2 agonist treatment. The therapeutic effects before and after the addition of omalizumab were compared. The lung function indicators (ratio of the forced expiratory volume [FEV] in the first second to the forced vital capacity, FEV in the first second, forced expiratory flow [FEF] at 50% of vital capacity, FEF at 75% of vital capacity, and maximum mid‐expiratory flow), fractionated exhaled nitric oxide values, asthma control test scores, rhinoconjunctivitis quality of life questionnaire scores, and urticaria control test scores were significantly different after 4 months of the regular administration of omalizumab (p < 0.05) compared with before administration. The use of omalizumab had a significant efficacy in the treatment of patients with AS, and the effects were obvious in the subgroups of patients with a combination of AS and atopic dermatitis, chronic urticaria, and allergic rhinitis. These results indicate that the treatment is worthy of clinical promotion.

Utilizing chest CT to assess the impact of omalizumab treatment on airway remodeling in refractory asthma

“…The study results showed that regardless of whether treatment lasted for a full four months or not, omalizumab therapy signi cantly reduced hospitalization days, lowered total hospitalization costs, and out-of-pocket expenses, while also signi cantly improving patients' asthmarelated subjective symptom scores. These ndings are consistent with results from other domestic and international studies [13,14].…”

Progress in diagnosis and treatment of difficult-to-treat asthma in children

“…By binding to free circulating IgE and downregulating IgE receptors on mast cells, basophils, and dendritic cells, it can reduce disease progression in allergic asthma. 157 Omalizumab is mainly used for severe refractory allergic asthma with elevated serum IgE levels (<1300 IU/mL) as classified in the fifth level of the Global Initiative for Asthma guidelines, and it can be administered to children over 6 years old. As a precision treatment, it has good safety and tolerability and can improve symptom control and quality of life in patients with severe refractory allergic asthma.…”